MedTrace Logo

Study of IMC-1121B in Patients With Advanced Solid Tumors Not Responding To Standard Therapy

NCT00786383 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 25

Last updated 2013-08-19

No results posted yet for this study

Summary

We are conducting a research study for tumors that have not responded to prior treatment. The subject will receive an investigational drug called IMC-1121B. ImClone LLC, the maker of IMC-1121B, is running this research study.

We believe that IMC-1121B blocks the growth factors made by the cancer cells, so new blood vessels do not grow. It is believed that without the new blood vessels, the cancer or tumor will not get the oxygen and food that it needs to grow. This may stop the cancer from growing or spreading and the tumor cells may die. Since normal blood vessels have already formed in adults, it might be possible to stop tumor growth without harming normal cells.

Conditions

Interventions

BIOLOGICAL

IMC-1121B

Cohort 1 6 mg/kg I.V., once every other week for 4 weeks

BIOLOGICAL

1121B

Cohort 2 8mg/kg I.V., once every other week for 4 weeks

BIOLOGICAL

1121B

Cohort 3 10 mg/kg I.V., once every other week for 4 weeks

BIOLOGICAL

1121B

Cohort 4 15 mg/kg I.V., once every 3 weeks for 6 weeks

BIOLOGICAL

1121B

Cohort 5 20 mg/kg I.V., once every 3 weeks for 6 weeks

Sponsors & Collaborators

Principal Investigators

  • Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST) · Eli Lilly and Company

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-02-28
Primary Completion
2009-01-31
Completion
2009-01-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00786383 on ClinicalTrials.gov